What’s new
PRESS RELEASE: Oxford Cancer Biomarkers closes funding round led by Plutus Investment Group LLP
OXFORD, UK – 3rd April 2023 – Oxford Cancer Biomarkers Ltd (OCB), a leader in AI-driven, precision cancer diagnostics, has
PRESS RELEASE: OncoHelix and Oxford Cancer Biomarkers Enter into a Partnership to Offer Breakthrough Cancer Genetic Screening Test to Canadians
OXFORD, UK – 20th March 2023 – Oxford Cancer Biomarkers (OCB) and OncoHelix today announce a new partnership to offer
PRESS RELEASE: Oxford Cancer Biomarkers granted Artificial Intelligence in Health and Care Award
OXFORD, UK – 3rd March 2023 – Oxford Cancer Biomarkers Ltd (OCB) announces today the receipt of an important AI
PRESS RELEASE: Oxford Cancer Biomarkers announces European expansion of life-saving chemotherapy toxicity test and independent, real-world evidence of patient benefit
ToxNav®, a CE-marked in vitro diagnostics product is now registered in the European database on medical devices (EUDAMED). Independent study
PRESS RELEASE: Oxford Cancer Biomarkers appoints Joanna Smart as Chair of the Board
OXFORD, UK – 6th January 2022 – Joanna Smart, an experienced Director and CEO in the life sciences sector has
Health Economics model for OncoProg® commissioned
Oxford Cancer Biomarkers Ltd partners with York Health Economics Consortium to demonstrate OncoProg ®
PRESS RELEASE: OncoProg receives CE mark
Oxford Cancer Biomarkers achieves CE mark for OncoProg ® digital pathology computational software product OXFORD, UK – July 19th,
PRESS RELEASE: Kyoung Mee Lee joins our Board of Directors
Oxford Cancer Biomarkers Ltd is pleased to announce that Kyoung Mee Lee has joined our Board of Directors. OXFORD,